RadNet, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless otherwise noted. RadNet operated 375 outpatient imaging centers across seven states. The company reports Imaging Centers and Digital Health segments; eRad was combined with the former AI segment in Digital Health, with prior-year segment data recast.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total service revenue | $431.7 million | $390.6 million | Up 10.5% |
| Income from operations | $11.3 million | $6.7 million | Up $4.7 million |
| Net income (loss) | $5.4 million | $(14.3) million | Improved $19.7 million |
| Net loss attributable to RadNet common stockholders | $(2.8) million; $(0.04) per share | $(21.0) million; $(0.36) per share | Loss narrowed |
| Adjusted EBITDA (non-GAAP) | $58.5 million | $48.2 million | Up 21.4% |
| Cash from operating activities | $17.1 million | $32.6 million | Down $15.5 million |
| Purchases of property and equipment | $57.4 million | $55.9 million | Up $1.5 million |
Operating margin was approximately 2.6% of revenue, compared with 1.7% in Q1 2023. Adjusted EBITDA margin was approximately 13.5%, versus 12.3%; both margins are calculated from reported figures. Operating cash flow less property-and-equipment purchases was negative $40.3 million, compared with negative $23.3 million; this is a simple calculation, not company-reported free cash flow.
At March 31, cash and cash equivalents were $527.0 million, up from $342.6 million at year-end. Working capital, excluding current operating lease liabilities, was $426.1 million. Total debt obligations were $834.6 million, including $821.2 million face value of term loans; reported long-term debt, net of current portion and discounts, was $814.4 million. No amounts were drawn on either revolving facility; $187.4 million remained available under Barclays after letters of credit, and $50.0 million under Truist. The company reported compliance with all credit covenants.
Financing cash flow included $218.4 million net proceeds from a March public offering of 5,232,500 shares at $44 per share, as well as proceeds from a subsidiary-interest sale and noncontrolling-partner contributions. The offering increased shares outstanding and funded much of the quarter-end cash increase.
Changes and operating drivers
- Imaging Center revenue rose 9.9% to $417.0 million. Same-center revenue increased 8.2%, driven by 1.6% procedure-volume growth, including 5.1% growth in advanced modalities, as well as mix and rate increases. Center count increased from 363 to 375.
- Digital Health revenue increased 32.3% to $14.7 million, reflecting eRad growth and rollouts of DeepHealth OS and enhanced breast cancer detection solutions. The segment recorded a $3.0 million operating loss and $3.7 million net loss.
- Operating costs rose 9.5% overall to $420.4 million. Management cited higher staffing to support volumes and wage inflation; salaries and professional reading fees, excluding stock compensation, increased 14.0%.
- Equity earnings from unconsolidated joint ventures increased to $4.3 million from $1.4 million. Interest expense was $16.3 million, up 3.5%; the company cited higher market rates, partly offset by swap receipts.
- Consolidated net income does not represent income attributable solely to RadNet shareholders: $8.2 million of Q1 2024 net income was attributable to noncontrolling interests.
Outlook, risks and notable items
- Management said existing capital, expected operating cash flow, and borrowing capacity should be sufficient for operations over the next 12 months and foreseeable future. The filing provides no specific revenue or earnings guidance.
- Management expects Digital Health to generate net losses over the next several years. Q1 included $3.3 million of non-capitalized R&D expense for DeepHealth Cloud OS and generative AI.
- On April 18, 2024, after quarter-end, RadNet refinanced its Barclays facilities with an $875.0 million term loan and a $282.0 million revolver. The new term loan has a stated margin of Term SOFR plus 2.5% or prime plus 1.5%, and matures in 2031; the revolver matures in 2029. The filing says the refinancing reduced interest rates and added approximately $167.9 million in cash after payoff and transaction costs. Quarterly term-loan principal payments increased to approximately $2.2 million.
- RadNet agreed to acquire Houston Medical Imaging for approximately $29.0 million and U.S. Imaging for approximately $4.2 million, with both transactions expected to close in Q2 2024. The filing does not provide subsequent closing status.
- Q1 acquisitions had preliminary purchase-price allocations. The remaining Heart and Lung milestone liability was settled for $3.6 million cash on April 1, 2024, after quarter-end; $4.6 million had been settled with shares in March.
- Interest-rate and foreign-currency exposures remain relevant. A hypothetical 1% increase in rates was estimated to increase annual interest expense by approximately $1.2 million on Barclays exposure and $1.4 million on Truist exposure, subject to stated assumptions. The company has no foreign-exchange contracts; a hypothetical 1% decline in relevant currencies was estimated to raise annual operating expenses by approximately $0.3 million.
- Management reported no material expected adverse impact from current legal proceedings, while noting litigation outcomes are uncertain. It also reported effective disclosure controls and no material change in internal control over financial reporting.
Key facts for investors to verify
- Whether same-center volume, pricing and advanced-modality mix gains continue, and how wage inflation affects operating margins.
- Whether operating cash flow improves after the working-capital-driven decline, relative to the company’s substantial capital spending needs.
- The realized borrowing costs and cash impact of the April refinancing, including the effect of variable rates and swap arrangements.
- Acquisition closing, integration, purchase-price allocation and performance for the Texas centers and Q1 acquisitions.
- Digital Health commercialization progress, recurring revenue growth, and the duration and scale of expected segment losses.
- The effect of equity issuance and noncontrolling interests on per-share results and RadNet common-stockholder earnings.